EGFR and non-small cell lung carcinoma: Nevertheless, our findings on the frequency of common driver mutations, especially EGFR, are largely consistent with other Asian studies [34,35], and the patients included reflect the real-world experience of the incorporation of plasma-based NGS into the NSCLC diagnostic paradigm.